Protalix BioTherapeutics, Inc. 4
4 · Protalix BioTherapeutics, Inc. · Filed Nov 3, 2014
Insider Transaction Report
Form 4
Manor Moshe
President & CEO
Transactions
- Award
Stock Options (Right to Buy)
2014-09-29+900,000→ 900,000 totalExercise: $2.37Exp: 2024-09-29→ Common Stock (900,000 underlying)
Footnotes (1)
- [F1]The options vest over a four-year period in 16 equal increments, subject to certain terms and conditions. Vesting of the options will be accelerated in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the issuer's 2006 Stock Incentive Plan, as amended.